Hallucinogen Psychedelic Mice Head twitch 5-Methoxy-N,N-diallyltryptamine 5-MeO-DALT 4-Acetoxy-N,N-diallyltryptamine 4-AcO-DALT 4-Hydroxy-N,N-diallyltryptamine a b s t r a c t Substantial effort has been devoted toward understanding the psychopharmacological effects of tryptamine hallucinogens, which are thought to be mediated by activation of 5-HT 2A and 5-HT 1A receptors. Recently, several psychoactive tryptamines based on the N,N-diallyltryptamine (DALT) scaffold have been encountered as recreational drugs. Despite the apparent widespread use of DALT derivatives in humans, little is known about their pharmacological properties. We compared the binding affinities of DALT and its 2-phenyl-, 4-acetoxy-, 4-hydroxy-, 5-methoxy-, 5-methoxy-2-methyl-, 5-fluoro-, 5-fluoro-2-methyl-, 5-bromo-, and 7-ethyl-derivatives at 45 receptor and transporter binding sites. Additionally, studies in C57BL/6 J mice examined whether these substances induce the head twitch response (HTR), a 5-HT 2A receptor-mediated response that is widely used as a behavioral proxy for hallucinogen effects in humans.
Introduction
Over the past decade there has been a renewed focus on the pharmacology and effects of serotonergic hallucinogens (Halberstadt, 2015; Nichols, 2016) . This focus has been driven, in part, by accumulating evidence that serotonergic hallucinogens may have therapeutic efficacy against anxiety, depression, substance abuse, and obsessive-compulsive disorder (Bogenschutz and Ross, 2017) . Additionally, although hallucinogen use has remained relatively stable over the past few decades, there has been a marked increase in the availability and diversity of hallucinogens in recent years that has resulted in numerous reports of untoward effects. Some of these hallucinogens are derived from N,N-diallyltryptamine (DALT). 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT), for example, was first synthesized by Alexander T. Shulgin (A.T. Shulgin, personal communication) , and was first marketed via the Internet in 2004 (Corkery et al., 2012) . According to Shulgin, oral doses of 12e20 mg produce psychoactive effects with a rapid onset and a relatively brief duration of 2e4 h (Shulgin and Shulgin, 2004) . Subsequently, 5-MeO-DALT and other DALT derivatives have become popular recreational hallucinogen; 5-MeO-DALT has been identified in many seized samples (Nagai et al., 2007; Rasanen et al., 2014; Strano Rossi et al., 2014; Odoardi et al., 2016; Brunt et al., 2017) and DALT and 4-acetoxy-N,N-diallyltryptamine (4-AcO-DALT) have also been detected (EMCDDA, 2008 (EMCDDA, ,2013 (EMCDDA, ,2015 .
Despite the widespread distribution and nonmedical use of diallyltryptamines (DALTs), very little is known about their pharmacology. It was previously reported that six DALT compounds bind non-selectively to 27 different receptors including 5-HT receptors (Cozzi and Daley, 2016) , and 5-MeO-DALT has been shown to act as a 5-HT 2A agonist (Arunotayanun et al., 2013) . However, few animal behavioral assessments have been performed with these compounds, and the resulting information could provide insight into the relationship between receptor binding and the behavioral effects of these drugs. Hence, the binding of DALT and nine ringsubstituted DALTs (see Fig. 1 ) were assessed at 45 receptor and transporter binding sites, followed by behavioral evaluation using the head twitch response (HTR).
Serotonergic hallucinogens produce the HTR, a brief paroxysmal head rotation in rats and mice, via activation of the 5-HT 2A receptor (Schreiber et al., 1995; Canal and Morgan, 2012; Halberstadt and Geyer, 2013) , the same receptor responsible for the psychedelic effects of hallucinogens in humans (Quednow et al., 2012; Kometer et al., 2013; Valle et al., 2016; Kraehenmann et al., 2017; Preller et al., 2017a,b) . The HTR is widely used as a behavioral proxy in rodents for human hallucinogenic effects because it is one of only a few behaviors that can reliably distinguish hallucinogenic and nonhallucinogenic 5-HT 2A receptor agonists (Gonzalez-Maeso et al., 2007) . We employed HTR studies with the ten DALT compounds in C57BL/6 J mice to test whether these tryptamines produce LSDlike behavioral effects in vivo.
In addition to producing effects via the 5-HT 2A receptor, tryptamine hallucinogens also bind to 5-HT 1A receptors with moderate to high affinity and efficacy (McKenna et al., 1990; Blough et al., 2014; Rickli et al., 2016) . The HTR induced by hallucinogens is attenuated by administration of 5-HT 1A receptor agonists such as 8-OH-DPAT, ipsapirone, and buspirone (Darmani et al., 1990; Schreiber et al., 1995; Kleven et al., 1997) , which is consistent with evidence for countervailing interactions between 5-HT 1A and 5-HT 2A receptors (Araneda and Andrade, 1991; Ashby et al., 1994; Krebs-Thomson and Geyer, 1998; Amargos-Bosch et al., 2004; Li et al., 2011) . In light of this apparent cross-talk, one unanswered question is whether the ability of tryptamine hallucinogens to induce the HTR via 5-HT 2A activation is modulated by their concurrent effects on 5-HT 1A receptors. Pretreatment with the mixed 5-HT 1A /b-adrenergic antagonist pindolol markedly augments the subjective response induced by the hallucinogen N,N-dimethyltryptamine (DMT) in human volunteers, suggesting that 5-HT 1A activation by DMT may blunt its 5-HT 2A -mediated effects (Strassman, 1996) . Based on those findings, we hypothesized that 5-HT 1A activation by tryptamine hallucinogens may buffer their ability to induce the HTR in mice.
One way to gauge the involvement of 5-HT 1A receptors in the behavioral response to hallucinogens is to assess the effect of combined administration with a 5-HT 1A antagonist. The possibility exists, however, that 5-HT 1A antagonists might alter the potency of 5-HT 2A receptor-mediated responses due to interactions that are known to occur between the receptors (Krebs- Thomson and Geyer, 1998; Salmi and Ahlenius, 1998; Li et al., 2011) . Indeed, 5-HT 1A antagonists can augment the HTR induced by hallucinogen administration (Willins and Meltzer, 1997) , and under certain conditions can even induce head twitches through a mechanism involving indirect activation of 5-HT 2A receptors (Darmani and Reeves, 1996; Darmani, 1998; Fox et al., 2010) . As an alternative to conducting antagonist blockade studies, receptor binding studies were conducted with DALT derivatives and regression analyses were performed to determine whether potency in the HTR assay is correlated with 5-HT 2A and/or 5-HT 1A receptor affinities.
Materials and methods

Subjects
Male C57BL/6 J mice (6e8 weeks old) obtained from Jackson Laboratories (Bar Harbor, ME, USA) were housed in a vivarium at the University of California San Diego, an AAALAC-approved animal facility that meets all Federal and State requirements for care and treatment of laboratory animals. Mice were housed up to four per cage in a climate-controlled room on a reverse-light cycle (lights on at 1900 h, off at 0700 h) and were provided with ad libitum access to food and water, except during behavioral testing. Testing was conducted between 1000 and 1800 h. All animal experiments were conducted in accordance with NIH guidelines and were approved by the UCSD animal care committee.
Drugs
The following drugs were tested: N,N-diallyltryptamine hydrochloride (DALT), 5-methoxy-N,N-diallyltryptamine hydrochloride (5-MeO-DALT), 5-fluoro-N,N-diallyltryptamine hydrochloride (5-F-DALT), 5-bromo-N,N-diallyltryptamine hydrochloride (5-Br-DALT), 4-hydroxy-N,N-diallyltryptamine hemifumarate (2:1) (4-HO-DALT), 4-acetoxy-N,N-diallyltryptamine fumarate (4-AcO-DALT), 2-phenyl-N,N-diallyltryptamine hydrochloride (2-Ph-DALT), 5-methoxy-2-methyl-N,N-diallyltryptamine hydrochloride (5-MeO-2-Me-DALT), 5-fluoro-2-methyl-N,N-diallyltryptamine hydrochloride (5-F-2-Me-DALT), and 7-ethyl-N,N-diallyltryptamine hydrochloride (7-Et-DALT). 4-AcO-DALT fumarate and 4-HO-DALT hemifumarate were obtained from Scientific Supplies (London, UK); the other tryptamines were synthesized, fully characterized, and available from previous studies (Meyer et al., 2014; Michely et al., 2015; Dinger et al., 2016; Brandt et al., 2017; Michely et al., 2017; Caspar et al., 2018) . 
Binding studies
A screening at 45 receptor and transporter binding sites was performed by the NIMH Psychoactive Drug Screening Program (NIMH PDSP). Most of these screenings were performed with cloned human receptors; exceptions are listed in Table 1 . Test compounds were dissolved in DMSO and were tested at 10 mM in competition assays against radioactive probe compounds. Sites exhibiting > 50% inhibition at 10 mM were tested in secondary assays at the identified receptor or transporter using 12 concentrations of the test compound, measured in triplicate, to generate competition binding isotherms. K i values were obtained from nonlinear regression of these binding isotherms from best-fit IC 50 values using the Cheng-Prusoff equation (Cheng and Prusoff, 1973 (Roth, 2013) .
Head-twitch response
The head twitch response (HTR) was assessed using a headmounted magnet and a magnetometer detection coil (Halberstadt and Geyer, 2013, 2014; Nichols et al., 2015) . Briefly, mice were anesthetized and a small neodymium magnet was attached to the dorsal surface of the cranium using dental cement. Following a two-week recovery period, HTR experiments were carried out in a well-lit room with at least 7 days between sessions to avoid carryover effects. Test compounds were dissolved in water containing 5% Tween 80 and administered IP at a volume of 5 or 10 mL/ kg body weight immediately prior to testing. Mice (n ¼ 5e6/group) were injected with drug or vehicle and then HTR activity was recorded in a glass cylinder surrounded by a magnetometer coil for 30 min. Coil voltage was low-pass filtered (2e10 kHz cutoff frequency), amplified, and digitized (20 kHz sampling rate) using a Powerlab/8SP with LabChart v 7.3.2 (ADInstruments, Colorado Springs, CO, USA), then filtered off-line (40e200 Hz band-pass). Head twitches were identified manually based on the following criteria: 1) sinusoidal wavelets; 2) evidence of at least two sequential head movements (usually exhibited as bipolar peaks) with frequency ! 40 Hz; 3) amplitude exceeding the level of background noise; 4) duration < 0.15 s; and 5) stable coil voltage immediately preceding and succeeding each response.
Data analysis
Head twitch counts were analyzed using one-way analyses of variance (ANOVA). Post hoc pairwise comparisons between selected groups were performed using Tukey's studentized range method. The entire 30-min recordings were examined for head twitches, but in some cases a shorter block of time was used for analysis to accommodate compounds with a brief duration-of-action (potency calculations can be confounded by extended periods of inactivity). ED 50 values and 95% confidence limits were calculated using nonlinear regression. Relationships between HTR potency and binding affinities were assessed using linear regression and ordinary least-squares regression. For all analyses, significance was demonstrated by surpassing an a-level of 0.05.
Results
Receptor binding
DALT and 9 ring-substituted derivatives were submitted to the NIMH PDSP for examination of their binding profiles at 45 neurotransmitter receptors and transporters. K i values were determined for compounds that produced > 50% displacement of a radioactive probe compound at a concentration of 10,000 nM. The results are summarized in Table 1 . The data for DALT and several of its 5-substituted derivatives (5-MeO-DALT, 5-F-DALT, and 5-Br-DALT) were reported in a previous publication (Cozzi and Daley, 2016 
and SERT (K i ¼ 150 nM). Incorporation of an oxygenated substituent at the 4-position altered the binding pattern of DALT. Compared to DALT, the 4-hydroxy and 4-acetoxy derivatives showed several-fold lower affinities for 5-HT 1A , 5-HT 2C , a 2A -adrenergic receptors, s 1 and s 2 sites, and SERT, whereas 5-HT 7 receptor affinity was increased by at least an order of magnitude. 4-Hydroxy-DALT also had low affinity for 5-HT 2B receptors (K i ¼ 2593 nM) and moderately high affinity for 5-HT 6 receptors (K i ¼ 213 nM). The 2-phenyl-substituted DALT derivative (2-Ph-DALT) showed a notable binding profile. The 5-HT 2A binding affinity of 2-Ph-DALT (K i ¼ 13 nM) was 54-fold higher than the affinity of DALT (K i ¼ 701 nM) and at least 10-fold higher than the affinity of any other DALT derivative. According to a previous report (Stevenson et al., 2000) , 2-aryl-tryptamines such as 2-phenyl-N,N-dimethyltryptamine and 2-phenyl-N,N-diethyltryptamine act as 5-HT 2A receptor antagonists and have high affinity (K i values of 4.4 nM and 2.8 nM, respectively, vs. Compared to the other compounds, 2-Ph-DALT also had relatively high affinity for a 1A and a 1D adrenoceptors and D 2 receptors. By contrast, 2-phenyl substitution abolished binding to s 1 sites and SERT. The 2-methyl derivatives of 5-MeO-DALT and 5-F-DALT were also examined. Incorporation of a 2-methyl group tended to reduce the affinity of those DALT derivatives for 5-HT receptors and SERT. The affinities of 5-MeO-DALT and 5-F-DALT for 5-HT 1A , 5-HT 1D , 5-HT 1E , 5-HT 2A , and 5-HT 2C receptors were consistently reduced by 2-methylation (see Table 1 ). Likewise, the binding of 5-MeO-DALT to SERT (K i ¼ 499 nM) was abolished by 2-methylation (5-MeO-2-Me-DALT: < 50% displacement at 10,000 nM), whereas the affinity of 5-F-DALT (K i ¼ 36 nM) was reduced almost 30-fold (5-F-2-Me-DALT; K i ¼ 983 nM).
Although 7-ethyl-substitution tended to reduce the binding affinity of DALT for most sites (including 5-HT 1A and 5-HT 2A receptors), the affinity of 7-Et-DALT for s 1 sites (K i ¼ 22 nM) was nearly 5-fold higher than the parent compound.
Head twitch response
DALT induced the HTR in mice with an ED 50 of 3.42 mg/kg. Compared to other N,N-disubstituted tryptamines such as N,Ndipropyltryptamine and N,N-diisopropyltryptamine (Smith et al., 2014) , DALT had relatively low potency. Similar to other tryptamine derivatives (Fantegrossi et al., 2008a) , the response to DALT followed an inverted-U-shaped dose-response function (see Table 2 ).
Ring-substitution on the DALT molecule resulted in active compounds, some of which were more potent than DALT (see Table 2 ). The 4-hydroxy and 5-methoxy derivatives induced the HTR with almost twice the potency of DALT. 4-Acetoxy-or 5-fluorosubstitution produced even greater increases in potency. By contrast, 5-bromo substitution did not significantly alter HTR potency relative to DALT. Substitution at the 2-position with either a methyl or a phenyl group (e.g., 2-Ph-DALT, 2-Me-5-MeO-DALT, 2-Me-5-F-DALT) abolished activity in the HTR assay. Similarly, 7-Et-DALT did not induce the HTR. In addition to having higher potency than DALT, the 4-hydroxy and 4-acetoxy derivatives produced a HTR with an extremely rapid onset (data not shown).
For (Fantegrossi et al., 2010) , SERT (Basselin et al., 2009) , and a 2 -adrenoceptors (Schreiber et al., 1995) . To test whether these other receptors play a role in the HTR induced by DALT derivatives, additional regression analyses were performed for sites with K i < 10,000 nM. There was no correlation between HTR potency and affinity at 5-HT 2C (R 2 ¼ 0.0292; F (1,4) ¼ 0.12, NS),
(1,4) ¼ 1.12, NS). Furthermore, affinity for these sites did not significantly predict HTR potency when analyzed in combination with 5-HT 2A receptor affinity using multiple regression (data not shown). a The experiments were performed using cloned receptors from the species indicated. b The experiment was performed using tissues or cells natively expressing the receptor.
Discussion
The potency and 5-HT receptor affinities of tryptamine hallucinogens are influenced by the substituent groups present on the indole nucleus and amine nitrogen. Most compounds in this structural class contain N,N-dialkyl substituents, but tryptamines containing N,N-diallyl groups have also been synthesized . Although the structure-activity relationships and pharmacology of dialkyltryptamines such as DMT and psilocybin have been widely investigated, relatively little is known about the comparative properties of diallyltryptamines. The present studies were conducted to investigate the pharmacology and behavioral effects of DALT and a variety of ring-substituted derivatives, some of which are used recreationally as new psychoactive substances or "research chemicals" and reportedly have hallucinogenic effects.
Consistent with the effects of other tryptamine hallucinogens (Fantegrossi et al., 2006 (Fantegrossi et al., , 2008b Halberstadt et al., 2011; Carbonaro et al., 2015; Nichols et al., 2015) , DALT and several of its derivatives substituted at the 4-or 5-position induced head twitches in mice. Although our studies measured 5-HT 2A binding affinity and did not include a functional assessment of receptor activation, DALT, 4-HO-DALT, 4-AcO-DALT, 5-Br-DALT, 5-F-DALT and 5-MeO-DALT are likely to be 5-HT 2A agonists based on their effects in the HTR assay. Importantly, 5-MeO-DALT was previously reported to act as an 9.2 ± 3.7 5 3.5
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agonist at recombinant human 5-HT 2A receptors (Arunotayanun et al., 2013) . Similarly, it was recently reported (Gatch et al., 2017) that 5-MeO-DALT produces full substitution in rats trained to discriminate the hallucinogenic 5-HT 2A receptor agonist 2,5-dimethoxy-4-methylamphetamine (DOM). Since the head twitch assay is routinely used to test whether 5-HT 2A agonists produce LSD-like behavioral effects (Gonzalez-Maeso et al., 2007) , the ability of diallyltryptamines to induce the HTR and produce DOMlike stimulus effects is thus consistent with their classification as serotonergic hallucinogens. However, few details have been published regarding the effects of these compounds in humans. Notably, the potency of the diallyltryptamines in the HTR assay is not correlated with 5-HT 2A receptor binding affinity alone but is dependent on activity at both 5-HT 1A and 5-HT 2A receptors. According to the multiple regression analysis, there is a positive relationship between HTR potency and 5-HT 2A affinity and a negative relationship between HTR potency and 5-HT 1A affinity; in other words, HTR potency increases as 5-HT 2A affinity increases and decreases as 5-HT 1A affinity increases. As noted earlier, the hallucinogen HTR occurs as a result of 5-HT 2A activation and can be suppressed by concurrent administration of a 5-HT 1A agonist (Darmani et al., 1990; Schreiber et al., 1995; Kleven et al., 1997) . Based on the roles that 5-HT 1A and 5-HT 2A receptors are known to play in the hallucinogen HTR, the regression analysis can be interpreted as showing that 5-HT 2A activation by DALT and its derivatives mediates the HTR, whereas their interaction with the 5-HT 1A receptor has a countervailing influence that inhibits expression of head twitch behavior. Hence, the potency of diallyltryptamines in the HTR assay may ultimately be determined by their combined activities at 5-HT 1A and 5-HT 2A receptors. These findings support the hypothesis that 5-HT 1A activation by tryptamine hallucinogens buffers their effects on the HTR.
Based on the ability of 5-HT 1A agonists to inhibit the HTR, there has been speculation that 5-HT 1A stimulation by nonselective tryptamine and lysergamide hallucinogens may reduce or inhibit the frequency of their induced head twitch behavior (Darmani et al., 1990) . Our recent work has demonstrated that the LSD analog and non-selective 5-HT 1A /5-HT 2A agonist lysergic acid morpholide (LSM-775) does not induce the HTR in mice unless the animals are pretreated with the 5-HT 1A antagonist WAY-100635 , indicating that 5-HT 1A activation by LSM-775 masks its ability to induce the HTR. As far as we are aware, however, the present study is the first to show that the potency of the HTR induced by tryptamine hallucinogens may be influenced by their 5-HT 1A interactions. Nevertheless, these findings remain tentative given to the small number of compounds tested; followup studies with a larger group of tryptamines are necessary to achieve more definitive results.
One potential confound for the regression analysis is that the binding studies were performed with cloned human 5-HT receptors whereas the behavioral experiments were performed in mice. Sequence differences between rodent and human 5-HT receptors can result in ligand binding affinity differences (Kao et al., 1992; Oksenberg et al., 1992; Parker et al., 1993; Smolyar and Osman, 1993) . There are reportedly species differences in the affinities of 4-hydroxytryptamines for the 5-HT 2A receptor, which are potentially relevant to our studies with 4-HO-DALT and 4-AcO-DALT. Specifically, according to Gallaher et al. (1993) , who studied human and rat 5-HT 2A receptors labeled with [ 3 H]ketanserin, 4-hydroxy-DMT (psilocin) has 15-fold higher affinity for the human receptor (K i ¼ 340 nM) than for the rat receptor (K i ¼ 5100 nM), whereas its 5-hydroxy isomer bufotenine has nearly equal affinities for the human and rat receptors (K i values of 300 nM and 520 nM, respectively). The human 5-HT 2A receptor contains a serine at position 242 in helix V whereas alanine is present in the receptor in rodents, leading Gallaher et al. (1993) to speculate that psilocin may have higher affinity for the human receptor because can form a hydrogen-bond with the 4-hydroxyl group in psilocin. Other studies, however, failed to confirm their findings. Another group reported that both psilocin and bufotenine displace [ tryptamines and ergolines based on mutagenesis experiments and molecular modeling (Nelson et al., 1993; Johnson et al., 1994; Almaula et al., 1996; Wacker et al., 2017) , abrogating the structural basis for the species differences posited by Gallaher. Therefore, although there is no clear evidence indicating that differences between human and mouse 5-HT receptors are likely to confound our regression analysis, especially with regard to 4-substituted DALT derivatives, the potential existence of cross-species differences in 5-HT receptor pharmacology must be acknowledged as a source of potential error for the regression. DALT and derivatives substituted at the 5-position have been
shown to bind to multiple 5-HT receptors, as well as a 2 adrenergic subtypes, s 1 and s 2 sites, histamine H 1 receptors, and SERT (Cozzi and Daley, 2016) . As shown in the present investigation, substitution at other positions in the indole ring can markedly alter the binding profile of DALT. The 4-substituted derivatives displayed reduced affinity at 5-HT 1A receptors compared to DALT and the 5-substituted derivatives. This is consistent with reports demonstrating that 4-hydroxy-DMT (psilocin) binds to 5-HT 1A sites with 20-fold lower affinity compared to its 5-hydroxy isomer (bufotenine) or the 5-hydroxy O-methyl derivative (5-methoxy-DMT), whereas there is little difference between their 5-HT 2A receptor affinities (McKenna et al., 1990; Blair et al., 2000) . Addition of a methyl group to the 2-position of 5-MeO-DALT reduced its affinity for most 5-HT binding sites, including 5-HT 1A and 5-HT 2A receptors, and abolished its ability to induce the HTR in mice at doses up to 14 mg/kg. These findings parallel those of Glennon et al. (2000) , who found that 2-methylation or 2-ethylation of 5-methoxy-DMT reduced its affinity for 5-HT 2A receptors. Similarly, although 2-methyl-5-methoxy-DMT is a hallucinogen in humans, it reportedly has significantly lower potency than 5-methoxy-DMT (Shulgin and Shulgin, 1997) . The 5-HT 2A receptor apparently has difficulty accommodating tryptamines with a 2-alkyl substituent.
2-Ph-DALT did not induce the HTR despite having the highest 5-HT 2A affinity of any compound screened (K i ¼ 13 nM). According to Stevenson et al. (2000) , various 2-phenyl-N,N-dialkyltryptamines including the N,N-dimethyl, N,N-diethyl, and N-methyl-N-ethyl homologues bind to the 5-HT 2A receptor with high (nM) affinities. However, all of these compounds blocked the stimulatory effect of 5-HT on phosphoinositide hydrolysis in CHO cells expressing the human 5-HT 2A receptor. In light of the fact that other 2-phenyl-N,Ndisubstituted tryptamines act as antagonists, the failure of 2-Ph-DALT to induce the HTR suggests that it may also act as a 5-HT 2A antagonist.
The 7-ethyl-substituted derivative of DALT also had low affinity for 5-HT 1A and 5-HT 2A receptors and did not induce the HTR in mice when tested at 15 mg/kg. These findings are consistent with the behavioral effects of other 7-ethyl-substituted tryptamines. 7-Ethyl-DMT produces only partial substitution in rats trained to discriminate 5-MeO-DMT from vehicle (Glennon et al., 1980a) . Rats trained to discriminate the interoceptive cue produced by 5-MeO-DMT generalize to other serotonergic hallucinogens (Glennon et al., 1980b; Young et al., 1982) ; hence, the absence of full substitution with 7-ethyl-DMT indicates that it does not produce hallucinogenlike stimulus effects in rodents.
The present findings also suggest that while 4-and 5-substituted DALT compounds may produce hallucinogenic effects in humans, 2-and 7-substituted DALT compounds may lack hallucinogenic effects, although further studies are necessary to test this hypothesis. While DALT, 5-MeO-DALT, and 4-AcO-DALT have already been detected by the European Early-Warning System and reported to the European Monitoring Center for Drugs and Drug Addiction (EMCDDA, 2013 (EMCDDA, , 2015 , no such reports have arisen for 2-or 7-substituted DALT compounds.
To our knowledge, this analysis is the first to quantify the relative contributions of 5-HT 2A and 5-HT 1A receptors to the induction of HTR by a class of tryptamine hallucinogens. These findings may allow us to better predict the psychoactive potential of DALT derivatives based on their behavioral pharmacology, and suggest that similar analyses could be attempted for other classes of tryptamine hallucinogens. However, although 5-MeO-DALT produces hallucinogen-like behavioral responses in rodent behavioral paradigms including mouse HTR (the present studies) and rat drug discrimination (Gatch et al., 2017) , it is not yet clear whether DALT derivatives can fully mimic the psychedelic effects produced by classical hallucinogens, allowing the possibility of subtle pharmacological differences relative to other tryptamine hallucinogens. Hence, it is not known whether the observed relationship between HTR potency and 5-HT 2A and 5-HT 1A binding affinities is consistent across the entire class of tryptamine hallucinogens. Nevertheless, if similar relationships do exist for other tryptamines, performing similar analyses on those classes should improve our understanding of their complex pharmacology and facilitate predictions regarding their psychoactive potencies.
